This inventor holds 1 USPTO granted patent. Top assignee: Dainippon Pharmaceutical Company, Limited. Active years: 1991.
Company Filing History:
Years Active: 1991
Title: Katuhisa Nakata: Innovator in Antitumor Polypeptide Research
Introduction
Katuhisa Nakata is a prominent inventor based in Nara, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of human TNF polypeptide mutants. His work has implications for cancer treatment, showcasing the potential of innovative biopharmaceuticals.
Latest Patents
Nakata holds a patent for "Novel human TNF polypeptide mutants and DNA's encoding said mutants." This patent describes a human TNF polypeptide mutant that possesses a modified amino acid sequence. The invention includes a DNA sequence that encodes this mutant and outlines a method for producing it by culturing a host transformed with a specific vector. Notably, the human TNF polypeptide mutant is soluble and exhibits antitumor activity, making it a valuable asset in cancer research.
Career Highlights
Katuhisa Nakata is affiliated with Dainippon Pharmaceutical Company, Limited, where he continues to advance his research. His work has been instrumental in exploring new therapeutic avenues for treating tumors. His innovative approach has garnered attention in the scientific community, contributing to the ongoing development of effective cancer treatments.
Collaborations
Nakata has collaborated with notable colleagues, including Junichi Yamagishi and Hitoshi Kawashima. These partnerships have fostered a collaborative environment that enhances the research and development of biopharmaceuticals.
Conclusion
Katuhisa Nakata's contributions to the field of biotechnology, particularly through his patent on TNF polypeptide mutants, highlight his role as an innovator in cancer research. His work at Dainippon Pharmaceutical Company, Limited, along with his collaborations, underscores the importance of teamwork in advancing medical science.